The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Natco Pharma intends to defend the matter accordingly
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
A significant proportion of healthcare professionals still tend to favor branded drugs
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Subscribe To Our Newsletter & Stay Updated
